To create a multi-centered prospective registry of individuals ≥60 years ("older adults") with IBD to quantify prevalence, incidence and progression of frailty, multi-morbidity, physical and cognitive impairment

EGID Partners is an online cohort of patients with eosinophilic gastrointestinal diseases (EGIDs), like eosinophilic esophagitis (EoE), eosinophilic gastritic (EG), eosinophilic gastroenteritis (EGE), and/or eosinophilic colitis (EC). It is a way to conduct important clinical research through surveys, and by filling out the initial survey, as well as follow-up surveys every 6 months, you can help answer important questions about living with EGIDs. We are also looking for people without EGIDs to provide information as well, so we can make comparisons between those do and don't have EGIDs. Adults as well as parents/caregivers of children are eligible. Find out more at www.egidpartners.org

The purpose of this study is to compare two different endoscopic techniques that are used to help patients feel better when they have a blockage from cancer in their stomach or first part of the small intestines.

Researchers are studying the long-term safety and tolerability of cendakimab for patients with eosinophilic esophagitis ("EoE"). The researchers hope to provide evidence to prove that cendakimab is a safe and effective medication for long-term EoE treatment.

This is an anonymous international research survey of primary care physicians (general practitioners), conducted to enhance understanding of diagnostic and treatment practices for irritable bowel syndrome (IBS) among such physicians in the U.S. and Europe, and to assess their knowledge and use of the Rome IV diagnostic criteria, which are the current recommended formal standard for diagnosis of the disorder.

we propose the creation of a prospective multi-center registry of patients with IBD and EIM, initially focusing on peripheral arthritis, the most common and understudied EIM, to better understand clinical course and management.

To learn if one kind of treatment approach, either (1) endoscopic surveillance or (2) endoscopic eradication therapy, is better, the same, or worse for treating patients with Barrett's esophagus and low-grade dysplasia.

For adults undergoing a standard of care biopsy for screening or surveillance of Barrett's Esophagus (BE). We are comparing two biopsy methods: Seattle biopsy versus WATS biopsy for the detection of intestinal metaplasia (change in the lining of your esophagus or 'food tube' to that of your stomach).

The primary endpoint for this study is subjects achieving either a decrease in Urgency Numeric Rating Scale (NRS) score of ≥ 2 points, or a decrease in score of ≥ 30%, at 12 weeks. Success is defined as ≥ 50% of enrolled subjects meeting the primary endpoint.